Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 5/20 | 0.58 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.45 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | TLR9 | Q9NR96 | 4/20 | 0.44 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.44 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 3/20 | 0.41 |
| ▸ | ATR | Q13535 | 2/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5226839 | 0.93 | TGFBR1 (0.67) | TGFBR1ROCK2JAK1TLR9TLR8 | |
| SCHEMBL5199410 | 0.84 | POLB (0.47) | TGFBR1TLR9TLR8TLR7ATR | |
| SCHEMBL5229192 | 0.83 | TGFBR1 (0.62) | TGFBR1ROCK2JAK1TLR9TLR8 | |
| SCHEMBL5199606 | 0.83 | TGFBR1 (0.82) | TGFBR1ROCK2DYRK1AHDAC4HDAC6 | |
| SCHEMBL5200577 | 0.82 | TGFBR1 (0.53) | TGFBR1DYRK1A | |
| SCHEMBL5230665 | 0.81 | TGFBR1 (0.49) | TGFBR1TLR9TLR8TLR7ATR | |
| SCHEMBL5199910 | 0.80 | RXRA (0.46) | TGFBR1 | |
| SCHEMBL5200634 | 0.80 | TGFBR1 (0.54) | TGFBR1HDAC6KDR | |
| SCHEMBL5226169 | 0.80 | TGFBR1 (0.46) | TGFBR1KDR | |
| SCHEMBL5198098 | 0.79 | TGFBR1 (0.42) | TGFBR1JAK1TLR9TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275968-A1 | Substituted Biphenyl Derivative | SANKYO COMPANY, LIMITED (JP) | 2007-11-29 | — | — | US | disclosed |
| EP-1798229-A1 | SUBSTITUTED BIPHENYL DERIVATIVE | Sankyo Company, Limited (JP) | 2007-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275968-A1 | Substituted Biphenyl Derivative | COL2A1, COL1A1, FGFR3 | TGFBR1 40/4885ROCK2 1213/4885JAK1 1663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.